Connecting Hydroxychloroquine In Vitro Antiviral Activity to In Vivo Concentration for Prediction of Antiviral Effect: A Critical Step in Treating Patients With Coronavirus Disease 2019.
Identifieur interne : 001631 ( Main/Corpus ); précédent : 001630; suivant : 001632Connecting Hydroxychloroquine In Vitro Antiviral Activity to In Vivo Concentration for Prediction of Antiviral Effect: A Critical Step in Treating Patients With Coronavirus Disease 2019.
Auteurs : Jianghong Fan ; Xinyuan Zhang ; Jiang Liu ; Yuching Yang ; Nan Zheng ; Qi Liu ; Kimberly Bergman ; Kellie Reynolds ; Shiew-Mei Huang ; Hao Zhu ; Yaning WangSource :
- Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [ 1537-6591 ] ; 2020.
English descriptors
- KwdEn :
- MESH :
- chemical , therapeutic use : Antiviral Agents.
- drug therapy : COVID-19.
- Humans, Hydroxychloroquine, SARS-CoV-2.
Abstract
Translation of in vitro antiviral activity to the in vivo setting is crucial to identify potentially effective dosing regimens of hydroxychloroquine. In vitro 50%/90% maximal effective concentration values for hydroxychloroquine should be compared to the in vivo free extracellular tissue concentration, which is similar to the free plasma hydroxychloroquine concentration.
DOI: 10.1093/cid/ciaa623
PubMed: 32435791
PubMed Central: PMC7314136
Links to Exploration step
pubmed:32435791Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Connecting Hydroxychloroquine In Vitro Antiviral Activity to In Vivo Concentration for Prediction of Antiviral Effect: A Critical Step in Treating Patients With Coronavirus Disease 2019.</title><author><name sortKey="Fan, Jianghong" sort="Fan, Jianghong" uniqKey="Fan J" first="Jianghong" last="Fan">Jianghong Fan</name><affiliation><nlm:affiliation>Division of Pharmacometrics, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Zhang, Xinyuan" sort="Zhang, Xinyuan" uniqKey="Zhang X" first="Xinyuan" last="Zhang">Xinyuan Zhang</name><affiliation><nlm:affiliation>Division of Pharmacometrics, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Liu, Jiang" sort="Liu, Jiang" uniqKey="Liu J" first="Jiang" last="Liu">Jiang Liu</name><affiliation><nlm:affiliation>Division of Pharmacometrics, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Yang, Yuching" sort="Yang, Yuching" uniqKey="Yang Y" first="Yuching" last="Yang">Yuching Yang</name><affiliation><nlm:affiliation>Division of Pharmacometrics, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Zheng, Nan" sort="Zheng, Nan" uniqKey="Zheng N" first="Nan" last="Zheng">Nan Zheng</name><affiliation><nlm:affiliation>Division of Pharmacometrics, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Liu, Qi" sort="Liu, Qi" uniqKey="Liu Q" first="Qi" last="Liu">Qi Liu</name><affiliation><nlm:affiliation>Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Bergman, Kimberly" sort="Bergman, Kimberly" uniqKey="Bergman K" first="Kimberly" last="Bergman">Kimberly Bergman</name><affiliation><nlm:affiliation>Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Reynolds, Kellie" sort="Reynolds, Kellie" uniqKey="Reynolds K" first="Kellie" last="Reynolds">Kellie Reynolds</name><affiliation><nlm:affiliation>Division of Infectious Disease Pharmacology, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Huang, Shiew Mei" sort="Huang, Shiew Mei" uniqKey="Huang S" first="Shiew-Mei" last="Huang">Shiew-Mei Huang</name><affiliation><nlm:affiliation>Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Zhu, Hao" sort="Zhu, Hao" uniqKey="Zhu H" first="Hao" last="Zhu">Hao Zhu</name><affiliation><nlm:affiliation>Division of Pharmacometrics, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Wang, Yaning" sort="Wang, Yaning" uniqKey="Wang Y" first="Yaning" last="Wang">Yaning Wang</name><affiliation><nlm:affiliation>Division of Pharmacometrics, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32435791</idno><idno type="pmid">32435791</idno><idno type="doi">10.1093/cid/ciaa623</idno><idno type="pmc">PMC7314136</idno><idno type="wicri:Area/Main/Corpus">001631</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001631</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Connecting Hydroxychloroquine In Vitro Antiviral Activity to In Vivo Concentration for Prediction of Antiviral Effect: A Critical Step in Treating Patients With Coronavirus Disease 2019.</title><author><name sortKey="Fan, Jianghong" sort="Fan, Jianghong" uniqKey="Fan J" first="Jianghong" last="Fan">Jianghong Fan</name><affiliation><nlm:affiliation>Division of Pharmacometrics, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Zhang, Xinyuan" sort="Zhang, Xinyuan" uniqKey="Zhang X" first="Xinyuan" last="Zhang">Xinyuan Zhang</name><affiliation><nlm:affiliation>Division of Pharmacometrics, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Liu, Jiang" sort="Liu, Jiang" uniqKey="Liu J" first="Jiang" last="Liu">Jiang Liu</name><affiliation><nlm:affiliation>Division of Pharmacometrics, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Yang, Yuching" sort="Yang, Yuching" uniqKey="Yang Y" first="Yuching" last="Yang">Yuching Yang</name><affiliation><nlm:affiliation>Division of Pharmacometrics, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Zheng, Nan" sort="Zheng, Nan" uniqKey="Zheng N" first="Nan" last="Zheng">Nan Zheng</name><affiliation><nlm:affiliation>Division of Pharmacometrics, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Liu, Qi" sort="Liu, Qi" uniqKey="Liu Q" first="Qi" last="Liu">Qi Liu</name><affiliation><nlm:affiliation>Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Bergman, Kimberly" sort="Bergman, Kimberly" uniqKey="Bergman K" first="Kimberly" last="Bergman">Kimberly Bergman</name><affiliation><nlm:affiliation>Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Reynolds, Kellie" sort="Reynolds, Kellie" uniqKey="Reynolds K" first="Kellie" last="Reynolds">Kellie Reynolds</name><affiliation><nlm:affiliation>Division of Infectious Disease Pharmacology, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Huang, Shiew Mei" sort="Huang, Shiew Mei" uniqKey="Huang S" first="Shiew-Mei" last="Huang">Shiew-Mei Huang</name><affiliation><nlm:affiliation>Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Zhu, Hao" sort="Zhu, Hao" uniqKey="Zhu H" first="Hao" last="Zhu">Hao Zhu</name><affiliation><nlm:affiliation>Division of Pharmacometrics, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Wang, Yaning" sort="Wang, Yaning" uniqKey="Wang Y" first="Yaning" last="Wang">Yaning Wang</name><affiliation><nlm:affiliation>Division of Pharmacometrics, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</title><idno type="eISSN">1537-6591</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral Agents (therapeutic use)</term><term>COVID-19 (drug therapy)</term><term>Humans (MeSH)</term><term>Hydroxychloroquine (MeSH)</term><term>SARS-CoV-2 (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>COVID-19</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term><term>Hydroxychloroquine</term><term>SARS-CoV-2</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Translation of in vitro antiviral activity to the in vivo setting is crucial to identify potentially effective dosing regimens of hydroxychloroquine. In vitro 50%/90% maximal effective concentration values for hydroxychloroquine should be compared to the in vivo free extracellular tissue concentration, which is similar to the free plasma hydroxychloroquine concentration.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">32435791</PMID><DateCompleted><Year>2021</Year><Month>01</Month><Day>27</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>28</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1537-6591</ISSN><JournalIssue CitedMedium="Internet"><Volume>71</Volume><Issue>12</Issue><PubDate><Year>2020</Year><Month>12</Month><Day>15</Day></PubDate></JournalIssue><Title>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</Title><ISOAbbreviation>Clin Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Connecting Hydroxychloroquine In Vitro Antiviral Activity to In Vivo Concentration for Prediction of Antiviral Effect: A Critical Step in Treating Patients With Coronavirus Disease 2019.</ArticleTitle><Pagination><MedlinePgn>3232-3236</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/cid/ciaa623</ELocationID><Abstract><AbstractText>Translation of in vitro antiviral activity to the in vivo setting is crucial to identify potentially effective dosing regimens of hydroxychloroquine. In vitro 50%/90% maximal effective concentration values for hydroxychloroquine should be compared to the in vivo free extracellular tissue concentration, which is similar to the free plasma hydroxychloroquine concentration.</AbstractText><CopyrightInformation>Published by Oxford University Press for the Infectious Diseases Society of America 2020.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fan</LastName><ForeName>Jianghong</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Pharmacometrics, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Xinyuan</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Division of Pharmacometrics, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Jiang</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Pharmacometrics, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Yuching</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of Pharmacometrics, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Nan</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Division of Pharmacometrics, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Qi</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bergman</LastName><ForeName>Kimberly</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reynolds</LastName><ForeName>Kellie</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Infectious Disease Pharmacology, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Shiew-Mei</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Hao</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Division of Pharmacometrics, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yaning</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of Pharmacometrics, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Infect Dis</MedlineTA><NlmUniqueID>9203213</NlmUniqueID><ISSNLinking>1058-4838</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber><NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Protocol" UI="C000705127">COVID-19 drug treatment</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="Y">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006886" MajorTopicYN="Y">Hydroxychloroquine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">COVID-19</Keyword><Keyword MajorTopicYN="Y">SARS-CoV-2</Keyword><Keyword MajorTopicYN="Y">antiviral activity</Keyword><Keyword MajorTopicYN="Y">hydroxychloroquine</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>05</Month><Day>01</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>5</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>1</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>5</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32435791</ArticleId><ArticleId IdType="pii">5841401</ArticleId><ArticleId IdType="doi">10.1093/cid/ciaa623</ArticleId><ArticleId IdType="pmc">PMC7314136</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001631 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 001631 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidChloroV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= pubmed:32435791
|texte= Connecting Hydroxychloroquine In Vitro Antiviral Activity to In Vivo Concentration for Prediction of Antiviral Effect: A Critical Step in Treating Patients With Coronavirus Disease 2019.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:32435791" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a CovidChloroV1
| This area was generated with Dilib version V0.6.38. |  |